• Follow us

Health

A Streamlined Pathway to Drug Approval

Randomized, placebo-controlled clinical trials have long been the gold standard for drug approval. Patients are assigned to either drug or placebo and the comparison between the two groups can provide meaningful data to allow the Food and Drug Association (FDA), pharmaceutical companies, physicians, and patients to understand whether the perceived drug effect (or safety signal) results from the drug or is the result of the placebo effect. While this approach to drug approval is undoubtedly good and often best, is it optimal for all patients? Specifically, is it optimal for children (and families) who have a rare debilitating disease that lacks reasonable treatment options?

Many of you will answer yes to these questions. Perhaps you believe that children living with rare and debilitating diseases are the most vulnerable and most deserving of protection. The parents of these children are also the most susceptible to the placebo effect and the most helpless when confronted with the claim of a miracle cure. You might say that these patients and families, perhaps above all others, deserve the full regulatory strength of the FDA to protect them from pharmaceutical companies.

But what if I told you that there is another way, a way that would allow patients to have more agency and accelerate breakthrough drug deployment? I challenge you to imagine that such a pathway should not only be possible but, under certain circumstances, would be the ethical choice. These circumstances would include the repurposing of an approved drug from one indication to another indication.

Perhaps other special situations would be rare diseases, or children, or grim medical conditions for which there are few options. I believe that there is a moral mandate to create such a pathway, and I urge the FDA and pharmaceutical companies to work together to create a path that allows special groups of patients under special situations to have accelerated access to 21st century cures.   

My son belongs to such a special group, and I have led a small cohort of families to observe, document and publish improvements in our children with Prader-Willi Syndrome (PWS). These improvements are unprecedented for this rare disease and the pathway I am proposing would acknowledge the experiences of our small group and place patients like my son in the center of the drug approval process. Such an approach would hasten the approval of therapies that appear to be safe and effective and improve the odds that patients like my son will live through the 21st century.

In particular, I urge the FDA to work with the pharmaceutical company that licensed the new drug pitolisant to leverage our published real-world patient experience data to create an alternative pathway that would allow the pharmaceutical company to expand its label from a first indication of narcolepsy to a second indication of PWS.

HOW I GOT HERE

My perspective comes from my experiences as a scientist and a mother of a child with a rare disease. My formal training in biology began at Macalester, a small liberal arts college, where I fell in love with the scientific process and developed fluency in discussing paradigm shifts and scientific explosions. I was fascinated by the story of Pasteur who demonstrated the efficacy of the rabies vaccine by administering an untested vaccine to a child doomed to die. He did this in response to a mother’s plea to save her son’s life.

After college, I went on to earn a PhD in immunology from Northwestern’s medical school. I did my thesis work in neuroimmunology and postdoctoral work in cellular immunology. While I never lost my love of benchwork, I chose to leave the laboratory, and stay home to raise my children.

While I missed science, I started a career as a medical writer, a job that I could do from home. I covered the incremental steps of medical research, the sporadic controversy and, occasionally, the breakthroughs. I was thrilled to write about the renegade ophthalmologist who treated a patient who was going blind from macular degeneration with a novel therapy. This doctor decided that the patient’s case was hopeless and thus acted on a scientific hunch. He injected a cancer drug, an antibody to vascular endothelial growth factor A, into the eye of the patient. The patient regained sight and the treatment of age-related macular degeneration was forever transformed.

I interviewed scientists and physicians, wrote about medical research, and raised children. I had two beautiful healthy girls followed by a beautiful boy with the rare disease PWS. PWS is known primarily as an endocrinological disease because it has the hallmark features of hyperphagia (constant eating) and obesity.

Once my son was born, I became immersed in the world of PWS. I observed my son closely; I read the medical literature; and I joined the tribe of PWS Moms that formed first on listservs and then on Facebook. As I observed, and read, and shared, I grew to see PWS as a neurological disease—one best treated with neurological supplements and a ketogenic diet.

With this novel approach, my son did well. When he turned 11, however, our world stopped as he experienced a crisis that resembled severe cataplexy and, on multiple occasions, rendered him unresponsive for agonizing minutes. I dove into the medical literature and found a drug recommended for approval in Europe for the treatment of narcolepsy. This first-in-class drug had not yet been approved anywhere in the world, but it was being investigated for many different endpoints. I read the mouse studies and the human studies, and, in totality, the data seemed to be a perfect fit for PWS. The only real disconnect was that it required thinking about PWS as a neurological condition as opposed to an endocrinological condition.

Of course, as a new drug, pitolisant lacks long-term human studies assessing its safety (and efficacy). That said, pitolisant has an excellent safety profile. It is an effective treatment against narcolepsy, and it has a demonstrated ability to normalize sleep-wake states, so much so that it was given breakthrough drug status by the FDA for the treatment of narcolepsy. Pitolisant also had the potential to affect many other problems associated with PWS such as hunger, cognition and muscle tone. For all these reasons, my husband and I reached out to our pediatrician and endocrinologist for help accessing pitolisant. Our son’s response to pitolisant was extraordinary and we caught sight of a future that before pitolisant would have been impossible.

To further assess the benefits of pitolisant, we partnered with a technology-minded PWS Mom to form Chion Foundation and recruited PWS families who wanted to try the drug. We brought the drug to the U.S. via personal importation allowed at the FDA’s discretion and crowdsourced our patient experience data. These dedicated families paid a great deal of money for the medication and reported their experiences, good and bad. We published these novel results in the medical literature as a clinical vignette last month and we have presented our findings at the annual meeting of the American Academy of Neurologists and the national SLEEP meeting. We now have years of data in 10 children with PWS aged two to 16 years.

At approximately the same time that we discovered pitolisant and began to systematically document our patient experience, the U.S. Congress enacted the 21st Century Cures Act. This act tasked the FDA with developing a program to evaluate the use of real-world evidence (i.e., multiple sources of information on health care outside of typical clinical research settings, including patient experience data) in the development of medical products. One such designated use of patient experience data is to add an indication to labeling of an approved drug.

The FDA has responded to the congressional mandate by developing a framework for the use of real-word evidence as well as some initial guidance on patient-centered drug development. We gathered our data in agreement with and in response to this growing realization that there should be a role for real-world data in the drug approval process.

WHAT DO WE KNOW ABOUT PITSOLIANT AND PWS?

In children with PWS (based on the initial sample of 10), pitolisant normalizes sleep-wake states, improves cognition, and appears to normalize the children’s relationship to food. It is well-tolerated, with only one of 10 children having to discontinue the drug because of irritability and behavioral issues. These issues returned to baseline quickly after the child stopped taking pitolisant.

A pharmaceutical company has licensed pitolisant to bring it to the U.S., and it will likely be approved for the treatment of narcolepsy in adults this fall. An investigation for the same use in children is under way in Europe. The pharmaceutical company has indicated a willingness to begin clinical trials in PWS.

THE IMPORTANCE OF PATIENT EXPERIENCE DATA

Unfortunately, while stakeholders agree that patient experience data should be used, there is little precedent for implementing it into the drug approval process. So, here we stand: we have collected the data; we have published the data; but we have no path for directly using the data to improve our population’s access to pitolisant. Our experience is thus a demonstration of the substantial hurdles between the intentions of the 21st Century Cures Act and the reality of the current drug approval process.

Yet, we continue to collect patient-reported outcomes from children with PWS who are benefitting from pitolisant. Each week, as word of the benefit of pitolisant spreads, new patients request prescriptions from their physicians and reach out to Chion Foundation for advice on how to access pitolisant for their children. For many families, the cost of pitolisant is an insurmountable barrier.

Nevertheless, the families begin to collect baseline data in hopes that once FDA has approved pitolisant for narcolepsy, their insurance company will cover it for PWS and they can contribute their experience to the overall understanding of the role of pitolisant as a treatment for PWS. They input their data on the TREND Community data collection platform, an online platform created in response to the Patient-Focused Drug Development initiative expanded by the 21st Century Cures Act to allow for the systematic gathering of patient experience data.

Each additional voice on TREND Community amplifies the message: pitolisant normalizes sleep-wake states, improves cognition and improves relationship with food. These effects translate into improved quality of life not only for our children with PWS but for their siblings and for us as caregivers. The FDA and the pharmaceutical company know of our patient experience data. They have been receptive and encouraging. While their interest and engagement are appreciated, however, it is not enough.

CREATING A NEW APPROVAL PATHWAY

Despite the enthusiasm for real-world evidence, patients continue to queue up for years as clinical trials unfold. Or rather, some patients do. Most families will find ways to access pitolisant, including, once it is approved, turning to insurance companies in the hopes that the insurance companies will cover pitolisant and allow them to see for themselves if pitolisant could help their children. The current reality is that as they do, we at Chion Foundation will continue to work as volunteers to collect patient experience data (both positive and negative) from those families that generously donate their time to document their experiences with pitolisant. Unfortunately, as it stands right now, underresourced parents (those who are poor, have poor health insurance, etc.) will not be able to access pitolisant.

Since we know that the reality is that patients with PWS will attempt to access pitolisant once it is available in the U.S., we ask that the pharmaceutical company and the FDA work together to take on the role that we are performing as volunteers. One way for this to happen is for the pharmaceutical company to perform not a randomized, controlled and prescriptive clinical trial but rather an open-label access study designed to gather both efficacy and safety data on patients with PWS who are aged two years (the age of the youngest child in our cohort) and older.

This would mean that physicians who would like to prescribe pitolisant to our patient population would enroll in the program and report data (both efficacy and adverse events) per the protocol. The protocol would suggest treatment guidelines but, unlike traditional clinical studies, administration of the drug would not be blinded and there would be no placebo. All patients would receive pitolisant free of charge.

The prescribing physician would maintain a primary loyalty to the patient and pitolisant dosing would be established according to each patient’s response to the drug. The data and patient response would be reported to the FDA and the pharmaceutical company as part of the open-label access program. Patients would be free to withdraw from the program at any time and for any reason.

The pharmaceutical company would likely be amenable to this idea. An open access program would have the benefit of facilitating rapid enrollment in the protocol and the freedom to explore more endpoints. Enrollment of rare-disease patients in such a program would almost certainly mean, however, that the pharmaceutical company would not have enough naive patients to enroll in a randomized clinical trial. Thus, accepting the open access path would mean rejecting the traditional clinical trial path. The pharmaceutical company would therefore need assurances from the FDA that data collected under an open access protocol can provide a foundation for adding a second indication to an already approved drug.

I believe that FDA will ultimately determine a path to drug approval that utilizes patient experience data. I also believe that the use of pitolisant as a treatment for PWS is an ideal candidate for a demonstration project of this path. It has several advantages: it is safe; it is not addictive; and, based on our experience, it appears to have a large treatment effect. As with all rare diseases, recruitment for a randomized PWS clinical trial will be challenging and an open access protocol offers a more effective approach to accelerating access to a promising, much-needed therapy.

Moreover, since PWS affects so many issues (cognitive, developmental, behavioral and physiological), any improvement in any one of those domains has the potential to change the trajectory of life for the child and the child’s family. Finally, physicians have successful experience prescribing this drug to children in the U.S. and in Europe.

An open access path to drug approval will require a rethinking, however, of some of the key aspects of how the FDA evaluates drugs for use in a given indication. For example, typically, drugs are approved based upon a dose-response curve. Clinical trial protocols often specify doses without actually knowing how individual patients will respond to doses. The open access approach would mean that data would be collected using a protocol that is dosed in a patient-centered way.

In addition, while it may be possible to consistently measure excessive daytime sleepiness across childhood and use this as an efficacy endpoint, other endpoints such as caregiver burden or clinical global impressions improvement in clinical symptoms may more effectively capture the patient experience. Use of these endpoints would be a recognition of our published real-world, patient experience data. It would also be an acknowledgement that children with PWS on pitolisant are experiencing global improvements in their symptoms beyond what we as parents would have believed possible.

THE ETHICAL SOLUTION

I thus propose that the ethical solution to the problem confronting families with PWS, a solution that is consistent with 21st Century Cures, is for the FDA to specify a path to drug approval that involves real-world, patient experience data. Such a path could take the form of an open access protocol that captures data from physicians prescribing pitolisant to patients with PWS aged two years and older. I acknowledge that the pharmaceutical company that is bringing pitolisant to market in the U.S. would be taking a risk by being the first to explore such a path. This risk, however, would likely save money, lives and families. I also note that this risk has also already been partially assumed by the PWS patients on pitolisant who have systematically gathered and published their data.

Rare-disease patients and caregivers live with an urgency that can be difficult to describe to scientists and those in the traditional drug development and approval pathway. We as patients and parents are left to play the role of the mother who brought her mauled son from rural Alsace to Paris to find Pasteur. We can deliver the patients and we can plead, but ultimately the scientists, the physicians and nowadays the regulatory authority, must help us find the path to access the drug.

Read More



Leave A Comment

More News

Scientific American: Health

Mind and Body Benefit from Two Hours in 2019-07-01 20:18:00People who spent at least two hours outside—either all at once or totaled over several shorter visits—were more likely to report good heal

Cannabis Could Help Solve the Opioid Crisis 2019-07-01 09:00:00Not alone, but it could be part of the solution -- Read more on ScientificAmerican.com

Social Media Bots Deceive E-cigarette Users 2019-07-01 09:00:00Social media bots promote unproved benefits of e-cigarettes -- Read more on ScientificAmerican.com

Genomic Surveillance Could Make a Big Difference in 2019-07-01 09:00:00It can flag pathogens long before patients show up in clinics -- Read more on ScientificAmerican.com

Meet the Ebola Workers Battling a Virus in 2019-07-01 08:00:00Nature's Amy Maxmen reports from the front line of the crisis in the Democratic Republic of the Congo -- Read more on ScientificAmerican.com

Mucus: The Body's Unsung Hero 2019-06-28 08:00:00The slimy stuff has a surprisingly wide array of beneficial biological functions -- Read more on ScientificAmerican.com

Democrats Divided on "Medicare for All" in First 2019-06-27 15:00:00Senator Elizabeth Warren and New York City Mayor Bill de Blasio were the only candidates in the first night in favor of eliminating private insurance

A Deeper Understanding of Breast Cancer 2019-06-27 07:00:00AI finds new insights into molecular tumor properties using images of cells and tissue -- Read more on ScientificAmerican.com

Going Barefoot Is Good for the Sole 2019-06-26 13:05:00Walking without shoes builds calluses, but that does not limit sensation -- Read more on ScientificAmerican.com

A Streamlined Pathway to Drug Approval 2019-06-26 07:00:00My son's case shows that an emphasis on patient experience data could foster drug development breakthroughs -- Read more on ScientificAmerican.com

Elite Runners' Microbes Make Mice Mightier 2019-06-24 23:25:00Mice that were fed bacteria isolated from elite athletes logged more treadmill time than other mice that got bacteria found in yogurt. -- Read more

Elite Athletes' Gut Bacteria Give Rodent Runners a 2019-06-24 13:30:00The chemical these bacteria produce appears to enhance athleticism -- Read more on ScientificAmerican.com

MedicineNet Daily News

AHA News: Summer Heat Brings Special Health Risks 2019-07-03 03:00:00Title: AHA News: Summer Heat Brings Special Health Risks for Pregnant WomenCategory: Health NewsCreated: 7/1/2019 12:00:00 AMLast Editorial Review: 7/

Gut Bacteria Supplements Might Boost Obese People's Health 2019-07-03 03:00:00Title: Gut Bacteria Supplements Might Boost Obese People's HealthCategory: Health NewsCreated: 7/1/2019 12:00:00 AMLast Editorial Review: 7/2/2019 12

Abuse, Injury More Likely When Child is With 2019-07-03 03:00:00Title: Abuse, Injury More Likely When Child is With Male Caregiver: StudyCategory: Health NewsCreated: 7/1/2019 12:00:00 AMLast Editorial Review: 7/2/

Add a Flavor Punch to Your Meals: Give 2019-07-03 03:00:00Title: Add a Flavor Punch to Your Meals: Give Pickled Veggies a TryCategory: Health NewsCreated: 7/2/2019 12:00:00 AMLast Editorial Review: 7/2/2019 1

Health Tip: IUD Fast Facts 2019-07-03 03:00:00Title: Health Tip: IUD Fast FactsCategory: Health NewsCreated: 7/2/2019 12:00:00 AMLast Editorial Review: 7/2/2019 12:00:00 AM

MS Linked to Higher Cancer Risk 2019-07-03 03:00:00Title: MS Linked to Higher Cancer RiskCategory: Health NewsCreated: 7/1/2019 12:00:00 AMLast Editorial Review: 7/2/2019 12:00:00 AM

Health Tip: Reducing PMS Symptoms 2019-07-03 03:00:00Title: Health Tip: Reducing PMS SymptomsCategory: Health NewsCreated: 7/2/2019 12:00:00 AMLast Editorial Review: 7/2/2019 12:00:00 AM

Soy's Heart Benefits Hold Steady Over Time, Review 2019-07-03 03:00:00Title: Soy's Heart Benefits Hold Steady Over Time, Review FindsCategory: Health NewsCreated: 7/1/2019 12:00:00 AMLast Editorial Review: 7/2/2019 12:0

Anti-Vaccine Movement a 'Man-Made' Health Crisis, Scientists Warn 2019-07-03 03:00:00Title: Anti-Vaccine Movement a 'Man-Made' Health Crisis, Scientists WarnCategory: Health NewsCreated: 7/2/2019 12:00:00 AMLast Editorial Review: 7/2

Packaged Vegetables Recalled by Growers Express 2019-07-03 03:00:00Title: Packaged Vegetables Recalled by Growers ExpressCategory: Health NewsCreated: 7/2/2019 12:00:00 AMLast Editorial Review: 7/2/2019 12:00:00 AM

Surgery Helps Babies Missing a Heart Chamber Survive, 2019-07-03 03:00:00Title: Surgery Helps Babies Missing a Heart Chamber Survive, But Problems LingerCategory: Health NewsCreated: 7/2/2019 12:00:00 AMLast Editorial Revie

Cancer Risk Rises After Iodine Rx for Overactive 2019-07-03 03:00:00Title: Cancer Risk Rises After Iodine Rx for Overactive Thyroid: StudyCategory: Health NewsCreated: 7/1/2019 12:00:00 AMLast Editorial Review: 7/2/201

Santé

Examen d'une patiente enceinte: «Comme si je venais 2019-07-02 05:00:00Le Dr Allan B. Climan a récemment été radié deux ans pour avoir tenu des propos à caractère sexuel en e

Éclosion de rougeole à Laval: le virus dans 2019-07-01 17:45:00Trois personnes infectées par la rougeole pourraient avoir disséminé le virus dans plusieurs lieux publics de Laval, fin juin, po

Pompes à insuline vulnérables aux cyberattaques 2019-07-01 09:50:00Certains modèles anciens de pompe à insuline peuvent être vulnérables aux cyberattaques, selon un avis transmis par Sant&ea

Une miraculée de l'épilepsie 2019-07-01 05:00:00Le 28 mai 2015, Zoé Sankowski mangeait tranquillement une collation quand elle s'est écroulée. Ses crises d'&eac

CHUM : des narcotiques « à volonté » pour une infirmière voleuse 2019-07-01 00:00:00À l'heure de la crise des opioïdes, une infirmière du CHUM a pu voler « plusieurs centaines » de doses de na

Des clients du Carrefour Laval pourraient avoir été 2019-06-30 14:06:00Des personnes qui étaient présentes au Carrefour Laval en fin de journée, mercredi dernier, pourraient avoir été ex

Prix de l'insuline: des Américains se tournent vers 2019-06-28 17:53:00La flambée du coût de l'insuline aux États-Unis a poussé un groupe de diabétiques américains à se ren

Institut Douglas: inquiétude autour d'un programme pour enfants 2019-06-28 05:00:00La santé des patients et du personnel de l'Institut universitaire en santé mentale Douglas, à Verdun, est compromise par un manq

Les aliments ultra-transformés liés à de nombreuses maladies, 2019-06-27 06:39:00Une nouvelle recherche révèle qu'une alimentation riche en aliments ultra-transformés est associée à l'obé

Virus du Nil occidental: gare aux maringouins! 2019-06-26 13:29:00Avec les beaux jours viennent les moustiques. Après un nombre record d'infections au virus du Nil occidental en 2018, les autorités de

Un médecin ontarien en fertilité utilisait son propre 2019-06-25 18:32:00Le Collège des médecins et chirurgiens de l'Ontario a révoqué le permis d'un spécialiste de la fertilité d

É.-U.: un enfant à l'urgence toutes les deux 2019-06-17 11:36:00Les produits de soins personnels ont envoyé un enfant à l'urgence aux deux heures chez nos voisins du sud entre 2002 et 2016, selon une

Radio-Canada | Santé

Des pompes à insuline vulnérables aux cyberattaques, avertit 2019-07-01 07:10:00Certains modèles anciens de pompe à insuline Medtronic MiniMed peuvent être à risque de cyberattaques, selon un avis transm

Des Américains font un millier de kilomètres pour 2019-06-29 16:41:00Les prix exorbitants de l’insuline aux États-Unis ont poussé des diabétiques américains à se rendre à

Les noyades en hausse au Québec depuis le 2019-06-29 15:24:00La Société de sauvetage du Québec lance un appel à la prudence sur les plans deau en ce début de saison estivale ma

Une Terre-Neuvienne met en garde les voyageurs contre 2019-06-29 09:18:00Lorsque Terri Murphy a gagné un voyage pour Cuba le mois dernier, elle s'attendait à revenir chez elle en pleine forme après un

David Saint-Jacques : trois semaines pour se sentir 2019-06-26 22:12:00Malgré un retour sur Terre éprouvant, le médecin de vol de l’astronaute David Saint-Jacques assure que son état de s

Le Québec a connu un nombre record de 2019-06-26 14:03:00Le nombre de cas d'infections au virus du Nil occidental (VNO) au Québec a fait un bond spectaculaire en 2018 pour atteindre un sommet jusque-

Deux premières naissances dans le cadre d'un programme 2019-06-26 11:53:00Les Cris de la Première Nation de Chisasibi, aux abords de la Baie James, célèbrent les deux premières naissances survenue

La zoothérapie a la cote auprès des psychologues 2019-06-16 07:31:00De plus en plus de professionnels se tournent vers la zoothérapie pour leurs interventions. Psychologues, psychoéducateurs et travailleu

2018, l'année où le plus de Québécois ont 2019-06-15 10:15:00Les Québécois seront-ils encore plus affectés en 2019 qu’en 2018 par le virus du Nil? L’année dernière

Les pharmaciens pourront prescrire et administrer des vaccins 2019-06-12 04:35:00C’est la deuxième étape du plan de la ministre québécoise Danielle McCann pour faciliter l’accès aux se

Augmentation des cas d'ingestion de détergent en sachet 2019-06-11 19:51:00Au Québec comme aux États-Unis, le nombre de personnes de plus de cinq ans qui se sont intoxiquées avec du détergent en sa

Global News : Health

Second-hand harm from alcohol ‘extremely prevalent’ according to 2019-07-01 15:14:49The study found that women were more likely to be harmed by a spouse, partner or family member, while men were more likely to be harmed by a stranger.

First Nations suicide rate 3 times higher than 2019-06-30 17:34:49The agency reported Friday on the rates of death by suicide for self-identifying First Nations people, Metis and Inuit from 2011 to 2016, compared to

Health Canada recalls Medtronic insulin pumps deemed vulnerable 2019-06-30 16:33:14The agency says cyberattacks could affect the device's settings which could result in an incorrect dose of insulin, but the agency is not aware of su

Burger wars: Is a plant-based patty always better 2019-06-30 06:00:57Many plant-based meat alternatives might not be that healthy for you, nutrition experts say.

Trump administration delays ‘conscience’ abortion rule 2019-06-29 18:23:28The rule allows medical workers to decline performing abortions or other treatments on moral or religious grounds.

Cybersecurity of medical devices under scrutiny after FDA 2019-06-29 17:19:08According to experts, however, this is not an anomaly. Medical devices, including medical implants, are likely vulnerable to cybersecurity breaches du

U.S. senator says Canada’s small population makes public 2019-06-29 09:13:02According to experts, the opposite is actually true.

What women need to know about getting their 2019-06-29 09:00:40Tubal ligation, or getting your "tubes tied," is a common surgical procedure that women have done for a variety of reasons.

Lactose-free cheeses review: Do they taste like the 2019-06-29 08:00:11Global News compares the presentation, texture and taste of five of the most popular lactose-free cheeses on the market.

How ‘trashy’ tourism threatens world-famous destinations 2019-06-28 17:46:42Tourism brings many benefits to a destination — including more money and jobs as well as cultural preservation — but its environmental imp

FDA approves ‘female Viagra,’ could tap potential $1 2019-06-21 21:15:26Vyleesi, chemically known as bremelanotide, activates pathways in the brain involved in sexual desire, helping premenopausal women with hypoactive sex

Health Canada warns ‘wakefulness-promoting drug’ may cause fetal 2019-06-21 16:26:35The FDA has labelled modafinil as a "wakefulness-promoting drug," that essentially helps patients with "excessive sleepiness."

Santé

Des pompes à insuline vulnérables aux cyberattaques 2019-07-02 04:16:24Certains modèles anciens de pompe à insuline Medtronic MiniMed peuvent être vulnérables aux cyberattaques, a fait savoir Sa

Une poupée réaliste qui a transformé sa fille 2019-07-02 01:00:00Une mère de famille de la Montérégie a vu sa fille autiste être transformée après qu’elle lui a confect

Nouvelle liste de lieux exposés à la rougeole 2019-07-01 20:40:34Une personne porteuse du virus de la rougeole et contagieuse a visité de nombreux commerces, en plus de circuler en transport en commun.

Comestibles au cannabis: commencez-vous à avoir faim? 2019-07-01 05:00:00L’arrivée prochaine des comestibles, un an après la légalisation du cannabis, nous permet d’entretenir l’id&eac

Encore une personne atteinte de la rougeole au 2019-06-30 15:03:10Une fois de plus, une personne atteinte de la rougeole a fréquenté le centre d’achat Carrefour Laval alors qu’elle ét

Des consultations à 275$ dans le confort de 2019-06-30 01:00:00Si la médecine à domicile est souvent considérée comme un vestige du passé, une entreprise privée qui offre

Quatre bambins contaminés à l’E. coli dans une 2019-06-29 18:51:10Les autorités ont indiqué que quatre enfants ont été contaminés par la bactérie E. coli après avoir v

Abus physiques et sexuels à la DPJ 2019-06-29 01:00:00Près du tiers des enfants sous la responsabilité de la DPJ de la Mauricie et du Centre-du-Québec ont subi des abus physiques ou s

Un mauvais médicament aurait causé la mort de 2019-06-29 01:00:00La famille d’une dame de 94 ans décédée en 2017 après s’être fait administrer la mauvaise médicat

273 nouveaux postes au CIUSSS la Capitale-Nationale, surtout 2019-06-28 23:08:27Dans les directions jeunesse, une centaine de postes s’ajouteront aux effectifs. La confirmation est arrivée en mai par le ministè

La grande séduction pour de futurs médecins 2019-06-28 18:45:18Quatorze étudiants en médecine visitent les hôpitaux du Bas-Saint-Laurent dans le but de savoir s’ils pourraient s’y p

Investir pour prévenir les retards de développement chez 2019-06-27 20:00:36Le gouvernement Legault souhaite diminuer l'attente pour les services aux enfants ayant des retards de développement.


Disclaimer and Notice:WorldProNews.com is not responsible of these news or any information published on this website.